Clinical Trial Update: Bioequivalence Study (Candesartan 16 mg and Amlodipine 5 mg) - A [Phase 1]

View source ↗

Summary

A Phase 1 bioequivalence study evaluating a fixed-dose combination of candesartan 16 mg and amlodipine 5 mg has completed, in hypertension.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension

Drugs mentioned

• Amlodipine (amlodipine)
• Candesartan (candesartan)

Snippet

Sponsor: Chong Kun Dang Pharmaceutical | Conditions: Hypertension | Phase 1 | Status: COMPLETED